相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Plasma osteoprotegerin, its correlates, and risk of heart failure: a prospective cohort study
Romina Di Giuseppe et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2017)
Prognostic value of plasma biomarkers in patients with acute coronary syndrome: a review of advances in the past decade
Richard Y. Cao et al.
BIOMARKERS IN MEDICINE (2016)
Osteoprotegerin: A novel biomarker for inflammatory bowel disease and gastrointestinal carcinoma
Floris A. E. De Voogd et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease
Stella Bernardi et al.
BIOMED RESEARCH INTERNATIONAL (2016)
Relationships of OPG Genetic Polymorphisms with Susceptibility to Cardiovascular Disease: A Meta-Analysis
De-Hua Song et al.
MEDICAL SCIENCE MONITOR (2016)
Osteoprotegerin Prevents Development of Abdominal Aortic Aneurysms
Batmunkh Bumdelger et al.
PLOS ONE (2016)
Relationship between osteoprotegerin and mortality in decompensated heart failure with preserved ejection fraction
Oscar Aramburu-Bodas et al.
JOURNAL OF CARDIOVASCULAR MEDICINE (2015)
Elevated Circulating Osteoprotegerin and Renal Dysfunction Predict 15-Year Cardiovascular and All-Cause Mortality: A Prospective Study of Elderly Women
Joshua R. Lewis et al.
PLOS ONE (2015)
Osteoprotegerin in Cardiometabolic Disorders
C. Perez de Ciriza et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2015)
Asymmetric Dimethylarginine and Cardiovascular Risk: Systematic Review and Meta-Analysis of 22 Prospective Studies
Peter Willeit et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
Influence of pre-analytical and analytical factors on osteoprotegerin measurements
C. Perez de Ciriza et al.
CLINICAL BIOCHEMISTRY (2014)
Osteoprotegerin is Secreted Into the Coronary Circulation: A Possible Association with the Renin-Angiotensin System and Cardiac Hypertrophy
S. Koyama et al.
HORMONE AND METABOLIC RESEARCH (2014)
Meta-analysis of genome-wide association studies identifies two loci associated with circulating osteoprotegerin levels
Johnny S. H. Kwan et al.
HUMAN MOLECULAR GENETICS (2014)
Effects of Combination Therapy With Olmesartan and Azelnidipine on Serum Osteoprotegerin in Patients With Hypertension
Hiroyasu Uzui et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2014)
Increased Calcification in Osteoprotegerin-Deficient Smooth Muscle Cells: Dependence on Receptor Activator of NF-κB Ligand and Interleukin 6
Andrea Callegari et al.
JOURNAL OF VASCULAR RESEARCH (2014)
Osteoprotegerin improves risk detection by traditional cardiovascular risk factors and hsCRP
Rasmus Mogelvang et al.
HEART (2013)
Relation Between Bone Mineral Density, Bone Loss and the Risk of Cardiovascular Disease in a Chinese Cohort
Cheng Shen et al.
AMERICAN JOURNAL OF CARDIOLOGY (2012)
Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop
Barbara Toffoli et al.
ATHEROSCLEROSIS (2011)
Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus
Jong Suk Park et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study
A. Vik et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Biomarkers of the Osteoprotegerin Pathway Clinical Correlates, Subclinical Disease, Incident Cardiovascular Disease, and Mortality
Wolfgang Lieb et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Osteoprotegerin as a Predictor of Coronary Artery Disease and Cardiovascular Mortality and Morbidity
Shreenidhi M. Venuraju et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-κB Ligand and Risk for Coronary Events A Nested Case-Control Approach in the Prospective EPIC-Norfolk Population Study 1993-2003
Anne G. Semb et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
B-Type Natriuretic Peptides and Cardiovascular Risk Systematic Review and Meta-Analysis of 40 Prospective Studies
Emanuele Di Angelantonio et al.
CIRCULATION (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Osteoprotegerin released from the vascular wall by heparin mainly derives from vascular smooth muscle cells
Mads Nybo et al.
ATHEROSCLEROSIS (2008)
Lack of Observed Association between High Plasma Osteoprotegerin Concentrations and Ischemic Stroke Risk in a Healthy Population
Mads Nybo et al.
CLINICAL CHEMISTRY (2008)
Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo
Giorgio Zauli et al.
BLOOD (2007)
Plasma osteoprotegerin levels in the general population - Relation to indices of left ventricular structure and function
Torbjorn Omland et al.
HYPERTENSION (2007)
Enhanced T-cell expression of RANK ligand in acute coronary syndrome -: Possible role in plaque destabilization
WJ Sandberg et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes
BA Mosheimer et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis
J Golledge et al.
STROKE (2004)
Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin
P Collin-Osdoby
CIRCULATION RESEARCH (2004)
Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease
S Kiechl et al.
CIRCULATION (2004)
Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-κB ligand and osteoprotegerin in plasma and serum
BYY Chan et al.
CLINICAL CHEMISTRY (2003)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
分享论文
